Oncotelic Narrows Losses, Posts Q2 Profit Amidst R&D Focus

TL;DR

**OTLC's Q2 profit is a mirage; the company is still bleeding cash and its 'going concern' status makes it a high-risk gamble.**

AI Summary

Oncotelic Therapeutics, Inc. (OTLC) reported a net income of $277,856 for the three months ended June 30, 2025, a significant improvement from a net loss of $209,837 in the same period of 2024. However, for the six months ended June 30, 2025, the company still posted a net loss of $20,860, though substantially reduced from the $618,513 net loss in the prior year. Revenue was not explicitly stated, but operating expenses decreased to $65,969 for the three months ended June 30, 2025, down from $96,582 in 2024. The company's total assets remained stable at $26,680,807 as of June 30, 2025, compared to $26,677,426 at December 31, 2024. A key financial change was the positive change in fair value of derivative on debt, contributing $484,198 in Q2 2025, compared to $23,630 in Q2 2024. The company continues to develop OT-101 for various cancers and COVID-19 through its joint venture with Dragon Overseas Capital Limited and GMP Biotechnology Limited, and is also evaluating other product candidates like OXi4503 and CA4P. OTLC faces a negative working capital of approximately $19.1 million as of June 30, 2025, and has accumulated losses of approximately $38.1 million since inception of Oncotelic Inc., raising going concern issues.

Why It Matters

Oncotelic's shift to a net income of $277,856 in Q2 2025, despite an overall six-month loss, signals a potential turning point for investors, especially given the significant reduction in net loss from $618,513 to $20,860 year-over-year for the six-month period. This improvement, driven by a favorable change in derivative liability, could attract speculative capital, though the persistent negative working capital of $19.1 million and accumulated deficit of $38.1 million highlight ongoing financial fragility. For employees and customers, continued R&D in OT-101 for cancer and COVID-19, along with other compounds, suggests long-term potential in a highly competitive biopharmaceutical market, but the company's 'going concern' status remains a critical competitive context.

Risk Assessment

Risk Level: high — Oncotelic Therapeutics, Inc. has incurred net accumulated losses of approximately $38.1 million since inception of Oncotelic Inc. and has a negative working capital of approximately $19.1 million at June 30, 2025. These factors, explicitly stated in the 'Liquidity and Going Concern' section, indicate substantial doubt about the company's ability to continue as a going concern.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence. While the Q2 2025 net income is positive, it's largely driven by non-operating adjustments like the change in fair value of derivative on debt. Focus on the company's ability to generate sustainable operating cash flow and address its significant accumulated deficit and negative working capital before considering any investment.

Financial Highlights

total Assets

$26,680,807

net Income

$277,856

cash Position

$108,022

Key Numbers

• $277,856 — Net income attributable to Oncotelic Therapeutics, Inc. (for the three months ended June 30, 2025, compared to a net loss of $209,837 in the prior year period.)
• $20,860 — Net loss attributable to Oncotelic Therapeutics, Inc. (for the six months ended June 30, 2025, a significant reduction from $618,513 in the prior year period.)
• $65,969 — Total operating expenses (for the three months ended June 30, 2025, down from $96,582 in the prior year period.)
• $484,198 — Change in fair value of derivative on debt (positive impact on income for the three months ended June 30, 2025, compared to $23,630 in the prior year period.)
• $38.1M — Accumulated deficit (since inception of Oncotelic Inc., indicating significant historical losses.)
• $19.1M — Negative working capital (as of June 30, 2025, highlighting liquidity challenges.)
• 434,929,966 — Shares of common stock outstanding (as of August 13, 2025.)
• $70,198 — Common shares issued upon conversion of debt (non-cash) (for the six months ended June 30, 2025.)
• $108,022 — Cash and restricted cash (at June 30, 2025, a slight increase from $106,128 at the beginning of the period.)
• $295,000 — Proceeds from short term loans (for the six months ended June 30, 2025, providing financing.)

Key Players & Entities

• Oncotelic Therapeutics, Inc. (company) — registrant
• Dragon Overseas Capital Limited (company) — joint venture partner
• GMP Biotechnology Limited (company) — joint venture partner
• Golden Mountain Partners (company) — affiliate of JV partners
• Fourth Man, LLC (company) — convertible note holder
• Mast Hill Fund, LP (company) — convertible note holder
• Blue Lake Partners, LLC (company) — convertible note holder
• Forever Prosperity, LLC (company) — assignee of GMP notes
• Peak One Opportunity Fund, L.P. (company) — equity purchase agreement counterparty
• Mosaic ImmunoEngineering, Inc. (company) — term sheet counterparty

FAQ

Risk Factors

• Going Concern and Liquidity Challenges [high — financial]: The company has accumulated deficits of approximately $38.1 million and faces negative working capital of approximately $19.1 million as of June 30, 2025. This raises substantial doubt about its ability to continue as a going concern.
• Dependence on Future Financing [high — financial]: The company's ability to fund its operations and development activities relies heavily on its ability to secure additional financing. Proceeds from short-term loans of $295,000 were obtained in the first six months of 2025, but this is insufficient for long-term sustainability.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The development of OT-101 and other product candidates is subject to extensive clinical trials and regulatory approvals from bodies like the FDA. Delays or failures in these processes can significantly impact the company's prospects.
• Reliance on Joint Ventures and Third Parties [medium — operational]: The development of OT-101 is conducted through a joint venture with Dragon Overseas Capital Limited and GMP Biotechnology Limited. The success of these collaborations is critical, and any disputes or failures in these partnerships could hinder progress.
• Competition in Oncology and COVID-19 Markets [medium — market]: The company operates in highly competitive markets for oncology treatments and COVID-19 therapies. Numerous established and emerging companies are developing similar or alternative solutions, posing a significant competitive threat.
• Fair Value of Derivative on Debt Volatility [medium — financial]: The company experienced a significant positive change in the fair value of derivative on debt ($484,198 in Q2 2025), which contributed to net income. However, this is a non-cash item and its future volatility could impact reported earnings.

Industry Context

Oncotelic Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on oncology and infectious disease treatments. The oncology market is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. The COVID-19 therapeutic space, while still active, is evolving rapidly with new variants and competing treatments.

Regulatory Implications

The company's product candidates, particularly OT-101, are subject to rigorous clinical trials and FDA approval processes. Any delays, adverse trial results, or failure to gain regulatory approval pose significant risks. The development is also subject to the regulations governing joint ventures and biotechnology partnerships.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Evaluate progress of clinical trials and regulatory submissions.
3. Assess the impact of non-cash items on reported earnings.
4. Understand the terms and performance of joint venture agreements.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported net income of $277,856 for the quarter, a significant improvement from a net loss in the prior year. Also reported negative working capital of $19.1 million and total assets of $26,680,807.
• 2025-06-30: Six Months Ended June 30, 2025 — Reported a reduced net loss of $20,860, compared to a larger loss in the prior year. Total operating expenses decreased to $65,969 for the quarter.

Glossary

Derivative on debt

A financial contract whose value is derived from an underlying debt instrument. Changes in its fair value can impact a company's reported income. (A significant positive change in the fair value of this derivative ($484,198 in Q2 2025) positively impacted Oncotelic's net income, though it is a non-cash item.)

Working capital

The difference between a company's current assets and current liabilities. Negative working capital indicates a potential short-term liquidity issue. (Oncotelic has a negative working capital of approximately $19.1 million as of June 30, 2025, highlighting significant liquidity challenges.)

Accumulated deficit

The total net losses a company has incurred since its inception. It represents a negative balance in retained earnings. (Oncotelic has an accumulated deficit of approximately $38.1 million, indicating a history of unprofitability and raising going concern issues.)

Going concern

An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company's significant accumulated deficit and negative working capital raise substantial doubt about its ability to continue as a going concern.)

Fair value

The price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. (The change in fair value of derivative on debt is a key driver of the reported net income improvement in Q2 2025.)

Year-Over-Year Comparison

Compared to the prior year period, Oncotelic Therapeutics has shown a significant improvement in its quarterly net income, moving from a loss of $209,837 to a profit of $277,856 for the three months ended June 30, 2025. The six-month net loss has also been substantially reduced. Operating expenses for the quarter decreased from $96,582 to $65,969. However, the company continues to face substantial liquidity challenges, evidenced by negative working capital of $19.1 million, and has a significant accumulated deficit of $38.1 million, indicating ongoing financial risks.

Filing Documents

• form10-q.htm (10-Q) — 1366KB
• ex31-1.htm (EX-31.1) — 20KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001641172-25-023568.txt ( ) — 7078KB
• otlc-20250630.xsd (EX-101.SCH) — 60KB
• otlc-20250630_cal.xml (EX-101.CAL) — 46KB
• otlc-20250630_def.xml (EX-101.DEF) — 280KB
• otlc-20250630_lab.xml (EX-101.LAB) — 409KB
• otlc-20250630_pre.xml (EX-101.PRE) — 352KB
• form10-q_htm.xml (XML) — 1112KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 ITEM 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 4 Consolidated Statements of Changes in Stockholders' Equity for the Three Months and Six Months Ended June 30, 2025 and 2024 5 Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 7

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 8 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 47 ITEM 4.

Controls and Procedures

Controls and Procedures 48

OTHER INFORMATION

PART II. OTHER INFORMATION 49 ITEM 1.

Legal Proceedings

Legal Proceedings 49 ITEM 1A.

Risk Factors

Risk Factors 49 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 49 ITEM 3. Defaults Upon Senior Securities 49 ITEM 4. Mine Safety Disclosures 49 ITEM 5. Other Information 49 ITEM 6. Exhibits, Financial Statement Schedules 50

SIGNATURES

SIGNATURES 52 2 PART I – FINANCIAL INFORMATION Item 1. Financial Statements ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, December 31, 2025 2024 ASSETS Current assets: Cash $ 88,022 $ 86,128 Restricted cash 20,000 $ 20,000 Accounts receivable 18,976 18,976 Prepaid & other current assets 10,594 9,107 Total current assets 137,592 134,211 In process R&D 1,101,760 1,101,760 Goodwill, net of impairment 2,788,230 2,788,230 Investment in GMP Bio at fair value 22,653,225 22,653,225 Total assets $ 26,680,807 $ 26,677,426 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 2,487,234 $ 2,437,167 Accounts payable to related party 347,084 346,057 Contingent consideration 2,625,000 2,625,000 Derivative liability on notes 278,786 703,616 Convertible and short-term debt, net of costs 9,940,174 9,790,866 Convertible debt and short-term debt - related party, net of costs 3,608,634 3,297,208 Convertible debt 3,608,634 3,297,208 Total current liabilities 19,286,912 19,199,914 Total liabilities 19,286,912 19,199,914 Commitments and contingencies (Note 13) - - Stockholders' equity: Common stock, $ .01 par value; 750,000,000 shares authorized; 408,292,720 and 407,289,888 issued and outstanding, respectively 4,082,927 4,072,899 Additional paid-in capital 42,279,570 42,219,400 Accumulated deficit ( 38,061,528 ) ( 38,040,668 ) Total Oncotelic Therapeutics, Inc. stockholders' equity 8,300,969 8,251,631 Non-controlling interests ( 907,074 ) ( 774,119 ) Total stockholders' equity 7,393,895 7,477,512 Total liabilities and stockholders' equity $ 26,680,807 $ 26,677,426 The accompanying footnotes are an integral part of these unaudited consolidated financial statements. 3 ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED Fo

View Full Filing

View this 10-Q filing on SEC EDGAR